MyAmyloidosisTeam

How do Attruby and tafamidis compare for treating amyloidosis?

Both Attruby (acoramidis) and tafamidis are FDA-approved medications that work similarly to treat ATTR amyloidosis affecting the heart. They both stabilize the TTR protein to prevent it from breaking apart and forming harmful amyloid deposits.

Key Show Full Answer

How do Attruby and tafamidis compare for treating amyloidosis?

Both Attruby (acoramidis) and tafamidis are FDA-approved medications that work similarly to treat ATTR amyloidosis affecting the heart. They both stabilize the TTR protein to prevent it from breaking apart and forming harmful amyloid deposits.

Key similarities:
* Both treat hereditary and wild-type ATTR cardiomyopathy (ATTR-CM)
* Both work by stabilizing the transthyretin protein
* Both are taken by mouth once daily

What we know about effectiveness:

Attruby was approved more recently (2024) and studies suggest it may significantly reduce serious heart risks, with early treatment potentially offering the most benefit over time.

Tafamidis has been available since 2019 and has longer-term data. Research shows it can slow disease progression and improve survival rates. In one large study, 93% of people with hATTR polyneuropathy treated with tafamidis were alive at 10 years.

Side effects differ slightly:

Attruby commonly causes diarrhea and mild stomach pain, with rare temporary kidney function changes.

Tafamidis may cause allergic reactions including trouble swallowing, hives, chest tightness, or fast heartbeat.

More research is needed to directly compare these medications head-to-head. Talk with your healthcare provider about which option might be best for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

8 Amyloidosis Treatments and Their Side Effects

5 ATTR Polyneuropathy Treatments and How They Differ